Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism

Current guidelines recommend low-molecular-weight-heparins (LMWH) monotherapy for 3 to 6 months as first-line treatment for cancer-associated venous thromboembolism (VTE). In clinical practice, enoxaparin and nadroparin are common agents used. However, differences in therapy adherence between these...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Wall, Sake J., Klok, Frederikus A., den Exter, Paul L., Barrios, Deisy, Morillo, Raquel, Cannegieter, Suzanne C., Jimenez, David, Huisman, Menno V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745948/
https://www.ncbi.nlm.nih.gov/pubmed/31723748
http://dx.doi.org/10.1097/HS9.0000000000000019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745948/
https://www.ncbi.nlm.nih.gov/pubmed/31723748
http://dx.doi.org/10.1097/HS9.0000000000000019

Ejemplares similares